130 related articles for article (PubMed ID: 15367700)
21. In vitro effect of cryptophycin 52 on microtubule assembly and tubulin: molecular modeling of the mechanism of action of a new antimitotic drug.
Barbier P; Gregoire C; Devred F; Sarrazin M; Peyrot V
Biochemistry; 2001 Nov; 40(45):13510-9. PubMed ID: 11695898
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and evaluation of the multidrug resistance-reversing activity of D-glucose mimetics of hapalosin.
Dinh TQ; Smith CD; Du X; Armstrong RW
J Med Chem; 1998 Mar; 41(6):981-7. PubMed ID: 9526572
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
24. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule.
Sessa C; Weigang-Köhler K; Pagani O; Greim G; Mora O; De Pas T; Burgess M; Weimer I; Johnson R
Eur J Cancer; 2002 Dec; 38(18):2388-96. PubMed ID: 12460783
[TBL] [Abstract][Full Text] [Related]
25. Preclinical anticancer activity of cryptophycin-8.
Corbett TH; Valeriote FA; Demchik L; Polin L; Panchapor C; Pugh S; White K; Knight J; Jones J; Jones L; LoRusso P; Foster B; Wiegand RA; Lisow L; Golakoti T; Heltzel CE; Ogino J; Patterson GM; Moore RE
J Exp Ther Oncol; 1996 Mar; 1(2):95-108. PubMed ID: 9414393
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
[TBL] [Abstract][Full Text] [Related]
27. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
Robey RW; Zhan Z; Piekarz RL; Kayastha GL; Fojo T; Bates SE
Clin Cancer Res; 2006 Mar; 12(5):1547-55. PubMed ID: 16533780
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and cytotoxicity studies of new cryptophycin analogues.
Liu WL; Zhang JC; Jiang FQ; Fu L
Arch Pharm (Weinheim); 2009 Oct; 342(10):577-83. PubMed ID: 19714674
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1.
Panda D; Himes RH; Moore RE; Wilson L; Jordan MA
Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554
[TBL] [Abstract][Full Text] [Related]
31. Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.
Weiss C; Figueras E; Borbely AN; Sewald N
J Pept Sci; 2017 Jul; 23(7-8):514-531. PubMed ID: 28661555
[TBL] [Abstract][Full Text] [Related]
32. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
33. Total synthesis and antitubulin activity of c10 analogues of cryptophycin-24.
Buck SB; Huff JK; Himes RH; Georg GI
J Med Chem; 2004 Jan; 47(3):696-702. PubMed ID: 14736249
[TBL] [Abstract][Full Text] [Related]
34. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
[TBL] [Abstract][Full Text] [Related]
35. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
36. N-methylsansalvamide a peptide analogues. Potent new antitumor agents.
Liu S; Gu W; Lo D; Ding XZ; Ujiki M; Adrian TE; Soff GA; Silverman RB
J Med Chem; 2005 May; 48(10):3630-8. PubMed ID: 15887970
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of TZT-1027 (Soblidotin).
Watanabe J; Minami M; Kobayashi M
Anticancer Res; 2006; 26(3A):1973-81. PubMed ID: 16827132
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological activities of hapalosin derivatives with modification at the C12 position.
Kashihara N; To-e S; Nakamura K; Umezawa K; Yamamura S; Nishiyama S
Bioorg Med Chem Lett; 2000 Jan; 10(2):101-3. PubMed ID: 10673089
[TBL] [Abstract][Full Text] [Related]
39. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity.
Bacher G; Nickel B; Emig P; Vanhoefer U; Seeber S; Shandra A; Klenner T; Beckers T
Cancer Res; 2001 Jan; 61(1):392-9. PubMed ID: 11196193
[TBL] [Abstract][Full Text] [Related]
40. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
